NCT06546488Recruiting
Cognitive Assessment Tools for Huntington's Disease.
Cognitive Assessment Tools for Individuals With Huntington's Disease.
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 76 (estimated)
- First submitted
- 12 Jul 2024
- Start date
- 20 Jun 2025
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Ohio State University
- Diseases
- Huntington's disease
- NCT number
- NCT06546488
What you commit to
- Study type: Observational
- Planned participants: 76
- From 20 Jun 2025 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
- Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
- Subjects with a history of a learning disability.
Age
- Age of symptom onset less than 19 years old or greater than 60 years old.
Other
- Subjects who are pregnant or breast feeding
- Subjects who are unable to provide consent.
Who the study is looking for
- Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
- Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
- A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
- Vision and hearing sufficient for compliance with tests.
- On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
Age in the registry: 30 years to 65 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Ohio State University -Wexner Medical Center Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.